# EDGAR Filing Document

**Accession Number:** 0001770069
**File Stem:** 0001900201-25-000006
**Filing Date:** 2025-10
**Character Count:** 7083
**Document Hash:** 168d0efea200ecca8d57be1bcdfeb1a3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001900201-25-000006.hdr.sgml**: 20251027

**ACCESSION NUMBER**: 0001900201-25-000006

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251025

**FILED AS OF DATE**: 20251027

**DATE AS OF CHANGE**: 20251027

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Catalyst4, Inc.
- **CENTRAL INDEX KEY:** 0001900201

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42914
- **FILM NUMBER:** 251420614

**BUSINESS ADDRESS:**
- **STREET 1:** 555 BRYANT STREET, NO. 376
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** 650-812-2614

**MAIL ADDRESS:**
- **STREET 1:** 555 BRYANT STREET, NO. 376
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MapLight Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001770069
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832163243
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-839-4360

**MAIL ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alvarado Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20190307

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Catalyst4, Inc.<br><sub>(Last) (First) (Middle)</sub><br>555 BRYANT STREET #376<br><sub>(Street)</sub><br>PALO ALTO, CA 94301<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>MapLight Therapeutics, Inc. [ MLPT ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-10-25 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series A Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Voting Common Stock | 148809 | <sup>(1)</sup> | I | See footnote<sup>(2)</sup> |
| Series A-1 Preferred Stock | <sup>(3)</sup> | <sup>(3)</sup> | Voting Common Stock | 444846 | <sup>(3)</sup> | I | See footnote<sup>(2)</sup> |
| Series B Preferred Stock | <sup>(4)</sup> | <sup>(4)</sup> | Voting Common Stock | 1263768 | <sup>(4)</sup> | I | See footnote<sup>(2)</sup> |
| Series B-1 Preferred Stock | <sup>(5)</sup> | <sup>(5)</sup> | Voting Common Stock | 275148 | <sup>(5)</sup> | I | See footnote<sup>(2)</sup> |
| Series C Preferred Stock | <sup>(6)</sup> | <sup>(6)</sup> | Voting Common Stock | 5444807 | <sup>(6)</sup> | I | See footnote<sup>(2)</sup> |
| Series D Preferred Stock | <sup>(7)</sup> | <sup>(7)</sup> | Voting Common Stock | 6678910 | <sup>(7)</sup> | I | See footnote<sup>(2)</sup> |

---

### Footnotes:

(1) The Series A Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

(2) The shares are held of record by Catalyst4, Inc. ("Catalyst4").  As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

(3) The Series A-1 Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

(4) The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

(5) The Series B-1 Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

(6) The Series C Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

(7) The Series D Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

**Signature:** /s/ Robert Brown  
**Date:** 2025-10-25

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**